Progyny (NASDAQ:PGNY) Price Target Raised to $23.00 at JPMorgan Chase & Co.

Progyny (NASDAQ:PGNY - Free Report) had its price target raised by JPMorgan Chase & Co. from $17.00 to $23.00 in a research note released on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities research analysts have also recently commented on the company. Canaccord Genuity Group decreased their target price on Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research note on Wednesday, November 13th. Truist Financial reiterated a "hold" rating and set a $19.00 target price (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of Progyny in a report on Tuesday, October 1st. Bank of America cut their price objective on shares of Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a research report on Wednesday, November 13th. Finally, Barclays decreased their target price on Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $25.50.

Progyny Trading Down 1.7 %

NASDAQ:PGNY traded down $0.41 during mid-day trading on Tuesday, hitting $23.13. 966,648 shares of the company's stock were exchanged, compared to its average volume of 1,997,851. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $42.08. The firm has a market capitalization of $1.97 billion, a P/E ratio of 39.89, a PEG ratio of 2.32 and a beta of 1.31. The company has a 50 day simple moving average of $17.46 and a 200-day simple moving average of $19.27.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same period in the prior year, the company posted $0.16 EPS. The business's revenue for the quarter was up 2.0% compared to the same quarter last year. As a group, analysts expect that Progyny will post 0.6 earnings per share for the current year.

Insider Transactions at Progyny

In other Progyny news, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction dated Monday, December 23rd. The stock was purchased at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the purchase, the chief executive officer now directly owns 441,463 shares of the company's stock, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman David J. Schlanger purchased 150,000 shares of the stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the transaction, the chairman now owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Progyny

Hedge funds and other institutional investors have recently bought and sold shares of the business. Acuitas Investments LLC bought a new stake in shares of Progyny during the fourth quarter valued at about $2,980,000. Baillie Gifford & Co. lifted its stake in Progyny by 52.2% in the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock worth $22,989,000 after purchasing an additional 456,853 shares in the last quarter. Entropy Technologies LP lifted its stake in Progyny by 5.5% in the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company's stock worth $826,000 after purchasing an additional 2,499 shares in the last quarter. Caitlin John LLC boosted its holdings in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after purchasing an additional 3,183 shares during the period. Finally, Vanderbilt University purchased a new position in shares of Progyny during the 4th quarter valued at $254,000. Institutional investors own 94.93% of the company's stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.